Satoreotide tetraxetan
- Generic Name
- Satoreotide tetraxetan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C74H98ClN19O21S2
- CAS Number
- 1039726-31-2
- Unique Ingredient Identifier
- EC1O2FB9FV
- Associated Conditions
- -
- Associated Therapies
- -
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 9
- Registration Number
- NCT03773133
- Locations
- 🇫🇷
CHU de Marseille - Hôpital la Timone, Marseille, France
🇩🇪Universitaetsklinikum Essen, Essen, Germany
🇨ðŸ‡University Hospital Basel, Basel, Switzerland
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 40
- Registration Number
- NCT02592707
- Locations
- 🇺🇸
MD Anderson Cancer Center, Department of Nuclear Medicine, Houston, Texas, United States
🇦🇺Peter MacCallum Cancer Centre, Molecular Imaging and Targeted Therapeutics Laboratory, East Melbourne, Australia
🇦🇺Ramsay Hollywood Private Hospital, Department of Nuclear Medicine, Perth, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath